HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $14

Benzinga · 03/12 11:43
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and raises the price target from $12 to $14.